CHronic Rhinosinusitis Outcome MEasures (CHROME), developing a core outcome set for trials of interventions in chronic rhinosinusitis by Hopkins, Claire et al.
ORIGINAL CONTRIBUTION
CHronic Rhinosinusitis Outcome MEasures (CHROME) – 
developing a core outcome set for trials of interventions in 
chronic rhinosinusitis*
Abstract 
Statement of problem: Evaluating the effectiveness of treatments in chronic rhinosinusitis (CRS) have been limited by both a 
paucity of high quality randomised trials, and the heterogeneity of outcomes in those that have been reported. 
Core outcome sets (COS) are an agreed, standardized set of outcomes that should be measured and reported by future trials as a 
minimum and will facilitate future meta-analysis of trial results in systematic reviews (SRs). We set out to develop a core outcome 
set for interventions for adults with CRS.
Method(s) of study: A long-list of potential outcomes was identified by a steering group utilising a literature review, thematic 
analysis of a wide range of stakeholders’ views and systematic analysis of currently available Patient Reported Outcome Measures 
(PROMs). A subsequent e-Delphi process allowed 110 patients and healthcare practitioners to individually rate the outcomes in 
terms of importance, on a Likert scale. 
Main results: After 2 rounds of the iterative Delphi process, the 54 initial outcomes were distilled down to a final core-outcome 
set of 15 items, over 4 domains.
Principal conclusions: The authors hope inclusion of these core outcomes in future trials will increase the value of research on 
interventions for CRS in adults. It was felt important to make recommendations regarding how these outcomes should be measu-
red, although additional work is now required to further develop and revalidate existing outcome measures.
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Aim 
To develop a core outcome set of outcome measures for trials 
evaluating the effectiveness of treatment interventions for 
adults with chronic rhinosinusitis.
Introduction
CRS represents a common and widespread source of ill health, 
with 11% of UK adults reporting CRS symptoms in a worldwide 
population study (1). CRS has been shown to have a major impact 
on quality of life that is reportedly greater in several domains of 
the SF-36 than angina or chronic respiratory disease (2). Acute 
exacerbations, inadequate symptom control and respiratory 
disease exacerbation are common amongst this population. 
Longitudinal primary care data from the Clinical Practice Re-
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search Datalink (CPRD) data shows that 1% of UK adults receive 
treatment from their GP each year with an average of 4 GP visits 
per year, receiving multiple prescribed medical treatments 
and with 91% of rhinosinusitis patients receiving an antibiotic 
prescription (3). There is a significant cost of the disease to the 
patient and healthcare systems, but also significant indirect 
costs through absenteeism and presenteeism. The total direct 
cost attributed to management of CRS is estimated to reach 
$11 billion per year in the USA (4). An earlier systematic review 
showed that the direct healthcare costs in the USA attributed to 
CRS is approximately $6.9 – 9.9 billion per annum, with indirect 
cost to society through lost productivity estimated at $13 billion 
per annum (5).
There is considerable variation in current practice, both in 
terms of antibiotic prescribing and surgical intervention rates 
(6, 7). This relates, in part, to the lack of strong recommendations 
in treatment guidelines. Recently, a suite of Cochrane reviews 
evaluating the effectiveness of treatments in CRS have been 
published, but they are limited both by a paucity of high quality 
randomised trials, and the heterogeneity of outcomes in those 
that have been reported, which precludes meta-analysis. 
Core outcome sets (COS) are an agreed, standardized set of 
outcomes that should be measured and reported by future trials 
as a minimum, and are not meant to be restrictive if trialists wish 
to include additional outcomes. However, inclusion of the core 
outcomes will facilitate future meta-analysis of trial results in 
systematic reviews (SRs). The heterogeneity of outcomes cur-
rently reported restricts our ability to combine results, and use 
of a COS may maximize the potential for a trial to contribute to 
future SRs. Furthermore, the use of core outcome sets also aims 
to reduce outcome reporting bias, where outcomes are measu-
red but left unreported, often in the setting of negative findings. 
The use of a COS is supported by the World Health Organisation 
(8) and the Cochrane Group for use in reviews of the effects of 
healthcare interventions, and they have already been developed 
and adopted by multiple medical and surgical specialties (9). The 
development of core outcome sets has been promoted and sup-
ported by the COMET (Core Outcome Measures in Effectiveness 
Trials) Initiative. The success of a COS is likely to be related to its 
simplicity, and an ideal of 3 – 4 main outcome measures were 
anticipated to be included in the final COS for CRS. Of course, 
due to the heterogeneity of symptoms that patients with CRS 
experience and the impact on their quality of life, restricting it to 
only a few outcomes was likely to be challenging. It should con-
sider both benefits and harms, and initially the core outcome set 
should consider ‘what’ to measure, rather than ‘how’ to measure 
it. Although considering trials of effectiveness, the outcomes 
selected are likely to be relevant to routine clinical practice. In 
rheumatology, the OMERACT group has developed 9 sets over 
the last 9 years, and now 70% of clinical trials report the COS. 
Although there is no specific methodology, the majority of core 
outcome sets follow a process of identifying existing know-
ledge to develop a long list of outcomes, followed by consensus 
methods using a Delphi process to achieve global agreement 
between different stakeholder groups, as recommended by 
COMET (10).
Materials and methods
COS development registration
The project was registered with the Core Outcome Measures 
in Effectiveness Trials (COMET) Register, and the development 
process followed guidance issued by COMET. In particular the 11 
minimum standards for COS development (11) were met and the 
checklist for reporting COS study reporting was followed (12).
Ethical approval was granted for patient participation in the 
focus group and Delphi process. Funding was awarded by the 
British Rhinologic Society to support the COS development.
Defining scope
A steering group of ENT surgeons active in clinical research in 
the field of CRS was assembled to consider the scope and design 
of the COS. It was agreed to consider all interventions for CRS, 
in adult patients (over 18 years). The COS is primarily aimed at 
research but it was felt that it would also be suitable for routine 
clinical care. 
Figure 1. Responses to OMIPP pilot project, grouped under main 
domains, %.
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field of CRS and are practicing ENT surgeons. A patient focus 
group was formed with patients recruited from clinical practice 
under the care of the lead author. Patients were selected with 
and without nasal polyps and at different stages of their patient 
journey.
Long-list development
A long-list of potential core outcomes was drawn up from a 
number of sources;
Stakeholder involvement
Both patients, researchers in CRS and physicians (including ENT 
specialists, Allergists, Respiratory physicians and primary care 
physicians) were involved in every stage of COS development, 
including defining scope, developing the long-list, the eDelphi 
process and review and analysis of the final results. 
A Steering Group was convened, consisting of authors of the Eu-
ropean Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 
Guideline, all of whom are actively engaged in research in the 
Table 1. Patient demographics, pre-operative clinical and laboratory tests.
Category Core-category Specific outcome/outcome measure used by trials
Changes in patient 
rated symptom 
severity
Global VAS (multiple different non-validated scales used), patient diary
Disease specific VAS for nasal blockage/congestion, nasal discharge, olfactory disturbance, facial pain/pres-
sure, headache, itching, sneezing, ocular symptoms. Clinical history for snoring, rhinitis, nasal 
obstruction, headache, dry mouth, loss of smell, use of medication
Quality of life
Global SF-36, SF-12, 7 point scale 
Disease specific SNOT 20/21/22, RSDI, RSOM-31, SNAQ-11, Chronic sinusitis survey
Physiological as-
sessments
Endoscopic VAS for adhesions, stenosis of ostia, patency of frontal recess, blood crusts, turbinate size.  
Polyp size using the Malm, Lindholt or Lund-Mackay scores. Descriptive text about mucosal 
oedema, discharge, crusting, scarring and swelling
Radiological CT using Lund-Mackay scores or Catalano and Payne for the frontal recess, MRI, X-ray
Nasal Airflow PNIF, PNEF
Mucociliary Function Saccharin clearance testing
Olfactory testing VAS scores, butanol threshold testing, carbinol sniff bottles, UPSIT, individual odours such as 
coffee, turpentine and lavender
Sinus manometry Active anterior rhinomanometry, acoustic anterior and posterior rhinomanometry
Microbiological
Microbiome Antral fluid culture, lavage culture, nasal swabs, Alternaria protein levels, middle meatus swab, 
nasal discharge swab
Fungal Hyphae As above
Lower Airway 
Disease
Patient reported outcome 
measures
Not assessed by any trial
Patient symptoms VAS for SOB, cough, wheeze, breathlessness, need for a B2 agonist
Respiratory function tests FEV1, FVC, VC, MEF50, histamine inhalation challenge, PEFR, exhaled NO
Side Effects
Medical Patient diary, epistaxis rates, plasma cortisol levels, serum ACTH, Ophthalmological ocular as-
sessment, urinary cortisol levels, oral candidiasis
Surgical Epistaxis, synechia, sinonasal infections, revision surgery
Acceptability of 
treatment
Compliance VAS, patient diary, empty medicine containers
Acceptability to patients Discomfort, length of improvement
Cost incurred by patient Not assessed by any trial
Cost to third party Not assessed by any trial
Patient preference Based on history from patient in only one RCT
Biomarkers
Nitric oxide, IL-8, IL-5, IL-4, serum eosinophils, mucous eosinophil derived neurostosin, α-2 
macroglobulin, IL-β, TNF-α in nasal lavage, mucosal biopsy for CD4, IL-4, MBP and T-cells.  Skin 
allergy testing, serum IgE, ESR, WCC, CRP
Other Need for rescue medication, rates of revision surgery
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1) Systematic search of outcomes used in Cochrane Systematic 
Reviews
A systematic search of outcomes used in randomised controlled 
trials included in Cochrane Systematic Reviews of interventions 
for CRS in adults or the Cochrane Central Register of Controlled 
Trials, was performed. All trials and reviews in adult patients 
were considered, including those in unselected CRS, those with 
and without polyps, and those with subtypes such as aspirin 
exacerbated respiratory disease and allergic fungal rhinosinusi-
tis.
The full text articles for the Cochrane systematic reviews were 
obtained and analysed for eligibility by two independent revie-
Patient reported symptoms
Overall symptom severity
Frequency of symptoms
Complete resolution of symptoms
Duration of symptoms
Duration of treatment effect
Individual symptoms
Sense of smell
Runny nose / Nasal discharge (anterior or posterior)
Nasal obstruction / blockage/congestion
Facial pain / pressure
Headache
Sleep disturbance
Fatigue
Itching / Sneezing
Epistaxis
Eye symptoms – dryness, itching, irritation
Ear symptoms – dizziness, fullness
Cough
Bad taste or bad breath
Dryness (nose or mouth)
Control of disease
Overall control of disease
Need for surgery
Occurrence of acute exacerbations
Ongoing treatment / healthcare utilisation
Quality of Life
Global quality of life
Disease specific quality of life
Impact on emotional wellbeing 
Mental ill-health
Ability to perform normal activities
Acceptability of treatment and side effects
Compliance with treatment
Acceptability of treatment
Costs of treatment to patients
Costs of treatment to third party payers
Side effects of treatment (including medical and surgical)
Treatment preference
Impact on lower respiratory (chest) conditi-
ons (including Asthma)
Lower respiratory (chest) symptoms 
Clinical measures of lower respiratory (chest) function
Medication usage for lower respiratory (chest) disease
Hospitalisation for chest disease
Clinical measures of the nose and sinuses
Endoscopic appearances (including presence/quality of pus, presence and size of polyps, oedema, 
crusting, inflammation) 
Radiological evaluation (by repeated CT / MRI imaging)
Evaluation of nasal airway using special tests (using either acoustic rhinometry/rhinomanometry/
PNIF/rhinospirometry)
Evaluation of mucociliary function (including saccharine testing/microscopy
Evaluation of sense of smell (olfactometry / Sniffin Sticks / UPSIT / Zurich/ etc.)
Maxillary sinus manometry
Microbiological
Changes in the individual Microbiome
Resistance to antibiotics in the community
Presence of fungal hyphae
Biomarkers
Eosinophil levels in serum
IgE levels in serum
Evaluation of exhaled nitric oxide in upper and lower respiratory tract
Mucosal Biopsies / histopathological specimens
Evaluation of nasal lavage
Serum Markers (IL-5, IL-8, TNFa, IL-4, ESR…..) – can be defined at a later stage
Table 2. Final long-list of items included in the Delphi process.
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social media campaign. Using direct emailing, social media and 
printed cards, an online survey was distributed to a wide range 
of people involved in the care of patients with CRS. Patients and 
practitioners were asked to list the 3 outcomes from treatments 
most important to them. Responses were analysed through 
development of a thematic framework based on the data. 
 
3) Systematic review of currently available Patient Rated Out-
come Measures (PROMs)
A systematic review previously undertaken in 2015 assessed 
all published PROMS for CRS (15). All included instruments were 
screened by 2 independent reviewers (ASJ and RL) to search for 
items or domains not included in the long list by the first two 
steps.
4) Patient and Steering Group review
Potential missing items were considered by a patient focus 
group, and the COS Steering Group, with particular reference to 
outcomes included in the EPOS guidelines (16). The long-list was 
then compiled and mapped to simplified domains for use in the 
wers (ASJ and RL). As each systematic review presents the results 
of a number of pooled clinical trials, the published papers for 
each individual trial were obtained. The bibliographies of the 
trial papers were further evaluated to identify additional studies 
for inclusion, not identified within the Cochrane systematic 
reviews themselves.
Two independent reviewers extracted data from all identified 
randomised trials. If there was uncertainty or disagreement 
amongst them, a third reviewer was consulted and had the 
final say. Each individual outcome was mapped to a core sub-
category. These sub-categories were then grouped into core 
categories. This process has been previously published, with the 
full methodology and results (13). 
2) Outcomes important to Patients, Practitioners and Provi-
ders (OMIPPP) 
This pilot project was commissioned by Cochrane UK to identify 
important outcomes interventions for CRS in adults (14). It sought 
the views of a wide range of practitioners (n=155) identified by 
professional societies and patients (n=80), identified using a 
Table 3. Round 1 responses. Table 4. Stability of median responses between rounds 1 and 2.
Median score for cohort and by stakeholder group, column 1 = whole 
cohort, 2=patients, 3=steering group, 4= all other HCPs. Items deemed 
important by all stakeholder groups after round 1 of Delphi highlighted 
in green.
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on the long-list, but the session was led and supported by an 
independent, trained facilitator. The facilitator summarised the 
views of the group and confirmed accuracy prior to concluding 
the meeting. As the lay definitions were thought to be clear and 
unambiguous by the Steering group, it was decided that there 
was no need for additional ‘medical definitions’.
Delphi process. 
Outcome definitions
A patient focus group was convened to determine the patient’s 
perspective on core outcomes, and create definitions for each 
outcome. Three ENT members of the Steering Group were avai-
lable to give a clinical overview for each individual outcome 
Table 5. Round 2 median scores by stakeholder group.
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(10), participants were able to rate the importance of each item 
and hence inclusion within the core outcome set. Participants 
were further asked to submit any outcomes thought to be 
important but missing from the long-list.
Additional outcomes listed by participants were reviewed and 
coded by two members of the study team (RH and CH) and new 
outcomes were included in round 2. In the second round, par-
ticipants were presented with the aggregate results of ratings 
for each item (the median score for each item was displayed, 
separately for each stakeholder group and for the combined 
cohort), allowing an opportunity of reflection, and were asked 
to consider each outcome again, using the same scoring system 
ranking each on a nine-point Likert scale. 
Consensus regarding whether an outcome should be included 
in the COS was defined a priori as 70% or more of the respon-
dents scoring it 7 to 9 and fewer than 15% scoring it as 1 to 3. 
Consensus that an outcome should not be included in the COS 
was defined as 70% or more scoring it as 1 to 3 and fewer than 
15% scoring it as 7 to 9. All other score distributions would be 
taken to indicate lack of agreement for inclusion of a given out-
come in the COS. In the event that different stakeholder groups 
Item Prioritization
We utilised an online Delphi technique (eDelphi software pro-
vided by the COMET initiative) inviting patients and healthcare 
practitioners to individually rate those outcomes from the long-
list that are thought to be essential for core outcome sets. There 
is currently no standard method for sample size calculation in 
the Delphi process, and thus a pragmatic approach was taken. 
We had aimed to achieve completed responses in round 2 from 
at least 100 participants, and therefore, allowing for 10% at-
trition between rounds, aimed to recruit at least 110 participants 
in the first round.
Participants for the Delphi process were recruited from the Stee-
ring Group, with further invitations sent to members of the BRS, 
ERS and ARS, primary care, allergists and respiratory medicine 
through the BSACI. Patient participants were recruited from 
clinical practice. Ethical approval for patient participation in the 
Delphi process and focus groups was granted.
In the first round, each participant was asked to consider each 
outcome item, and to decide which were essential to the core 
outcome set. By using the 10 point scale proposed by the 
GRADE group (17), where 1 to 3 signifies an outcome of limited 
importance, 4 to 6 important but not critical, and 7 to 9 critical 
Table 6. Items achieving consensus as essential for inclusion in the core outcome set.
Item No of Stakeholders rating order of Importance Overall %
Consensus for 
Essential DomainLittle Moderate Very
Compliance with treatment 0 3 60 95%
Nasal obstruction / blockage/congestion 0 4 63 94%
Overall control of disease 0 5 60 92%
Endoscopic appearances 1 4 57 92%
Acceptability of treatment 0 7 56 89%
Side effects of treatment (including medical and surgical) 1 8 54 86%
Overall severity of symptoms 0 10 59 86%
Disease-specific quality of life 0 9 55 85%
Frequency of symptoms 0 12 56 82%
Sense of smell (and taste) 0 12 55 82%
Length of symptoms 2 13 50 79%
Need for surgery 1 14 50 77%
Runny Nose (Nasal discharge) - anterior or posterior 2 15 50 75%
Ability to perform normal activities 3 13 47 75%
Length of treatment effect 0 18 48 72%
Table 7. Items achieving consensus to be excluded from the core outcome set.
Domain No of Stakeholders rating order of Importance Overall %
Consensus for Un-
important DomainLittle Moderate Very
Maxillary (cheek) sinus manometry 45 4 13 73%
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Table 8. Items failing to reach 70% consensus, but rated by the majority to be essential – may be considered in extended sets.
Item No of Stakeholders rating order of Importance Overall %
Consensus for 
Essential DomainLittle Moderate Very
Ongoing treatment requirements / Healthcare utilisation 2 19 44 68%
Radiological evaluation 3 18 41 66%
Complete resolution of symptoms 1 23 42 65%
Global quality of life 2 21 42 65%
Lower respiratory (chest) symptoms 0 24 38 61%
Treatment preference 0 25 38 60%
Facial pain / pressure 3 24 40 59%
IgE levels in serum 3 27 32 52%
Table 9. Remaining items – Items did not reach consensus definition for inclusion in the core outcome set, and were rated by majority of respondents 
as moderately important.
Item No of Stakeholders rating order of Importance Overall %
Consensus for 
Moderate DomainLittle Moderate Very
Itching /Sneezing 5 48 16 81%
Costs of treatment to third party payers 4 42 17 67%
Mucosal Biopsies / Histopathological specimens 6 40 16 65%
Headache 8 41 16 63%
(Nose Bleeds) Epistaxis 21 41 6 60%
Cough 13 39 13 60%
Mental ill-health 12 37 14 59%
Costs of treatment to patients 1 37 25 59%
Eye symptoms eg. dryness; itching; irritation 18 38 10 58%
Clinical measures of lower respiratory (chest) function 4 36 22 58%
Evaluation of sense of smell 8 36 18 58%
Change in the individual microbiome 7 36 19 58%
Emotional wellbeing and stability 8 36 19 57%
Serum Markers 13 35 14 56%
Dryness (nose or mouth) 22 36 7 55%
Ear symptoms; eg. dizziness; fullness 22 37 9 54%
Medication usage for lower respiratory (chest) disease 1 33 28 53%
Hospitalisation for chest problems 4 33 25 53%
Evaluation of the nasal airway using special tests 15 33 14 53%
Fatigue 13 35 20 51%
Bad breath and taste in the mouth 25 33 7 51%
Evaluation of mucociliary function 16 31 15 50%
Eosinophil levels in serum 2 31 29 50%
Resistance to antibiotics in the community 5 30 27 48%
Histological evidence of fungal hyphae 11 29 22 47%
Sleep disturbance 8 30 28 45%
Evaluation of nasal lavage 23 24 15 39%
Exhaled Nitric Oxide in upper & lower respiratory tract 24 23 15 38%
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disagreed about the inclusion of specific outcomes in the COS, 
only items about which there was consensus were included.
Two rounds of the Delphi process were initially planned, with 
stability measured by consistency of responses between suc-
cessive rounds of a study and used to determine the value of 
further rounds (18). The Steering group and two patient represen-
tatives considered the outcomes of each round of the Delphi, 
and approved the decision to end the Delphi process and the 
final core outcome set.
Results
Longlist development  
The SR identified a total of 83 randomised control trial papers 
and 8 Cochrane reviews. Of these, 14 trials were excluded, as 
they were trials that included either paediatric patients, those 
with allergic rhinitis or published conference abstracts. A total of 
69 RCTs were finally obtained and included within this study. No 
further references were identified through examination of the 
bibliography of the published systematic reviews or trials. Three 
hundred and sixty five individual outcomes were extracted from 
the clinical trials. The trials overlapped in their use of outco-
mes and between them had used 68 different outcomes and 
outcome measures. These were then mapped onto twenty-three 
pre-determined sub-categories, belonging to nine main core 
categories (Table 1). 
The OMIPP project generated 653 suggestions of important 
outcomes from 235 participants. Of these 549 (169 from people 
with rhinosinusitis, and 380 from practitioners) fitted our des-
cription of an outcome. These were mapped onto eight domains 
and combined with the longlist above (Figure 1; responses 
grouped under main domains). Of note there was consistency 
with the domains identified in the SR and those identified with 
qualitative analysis of the response to the OMIPP project
Finally, a focus group of 10 patients with CRS and the Steering 
group reviewed the list to ensure that no missing items could be 
identified. A final long-list of 54 items, mapped onto 9 domains 
was developed (Table 2).
Delphi Process
The first round of the Delphi process was held in April 2017. One 
hundred and fourteen participants were recruited, achieving 
our initial target; this included 8 Steering Group members, 19 
patients, and 88 physicians from primary care/allergy/ENT, with 
ENT surgeons and allergy accounting for 91% of the latter group. 
There was close agreement between the Steering group and 
other healthcare providers (HCPs) (Table 3). In contrast, there 
were marked differences in responses amongst patients; while 
patients also rated those items thought by both the Steering 
Group and other HCPs to be essential to a COS, they also rated 
almost all clinical measures as essential, even though these were 
not rated highly by clinicians. Fifteen items were considered es-
sential to the core outcome set by all respondents. 
Unfortunately, there was a significant drop-out in respondents 
between round 1 and 2, despite sending multiple reminders. At 
round 2, we received 67 replies, representing 59% of our initial 
Table 10. Final Item list for inclusion in Core Outcome Set for CRS, including proposed measurement tools
Domain Item Proposed measurement tool
Patient reported 
symptoms and QOL
Overall symptom severity
Frequency of symptoms
Duration of symptoms
Duration of treatment effect
Sense of smell
Runny nose / Nasal discharge (anterior or 
posterior)
Nasal obstruction / blockage/congestion
Disease specific quality of life
SNOT-22 repeated over time
Additional question required to address fre-
quency of symptoms
Control of disease Overall control of disease
Need for surgery
Endoscopic appearances (including presence/
quality of pus, presence and size of polyps, 
oedema, crusting, inflammation)
Need for systemic medication (steroid or 
antibiotic)
Progression to surgery
Lund-Kennedy score
Impact on daily activity Ability to perform normal activities SNOT-22
(or specific measures of productivity)
Acceptability of treatment and side effects Compliance with treatment
Acceptability of treatment
Side effects of treatment (including medical 
and surgical)
Measurement of compliance and side effects
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cohort. There was a high level of stability in the overall median 
scores for each item from round 1 to round 2 (Table 4). The over-
all category (not important / moderate importance / essential to 
COS) only changed in 4 out of 54 items. Twenty-three items had 
a median score rating the item as essential to the core outcome 
set. There was much greater consistency in categorical rating 
between stakeholder groups and it was agreed that there was 
no need for a third round (Table 5).
When looking at items that met our definition of consensus, 15 
items were considered essential to the core outcome set (Table 
6), with >70% rating as 7 or more, and less than 15% rating as 3 
or less; 1 item was agreed to be unimportant (Table 7). Overall, 8 
items were rated as essential by the majority of respondents but 
did not reach the 70% threshold (Table 8), while the remainder 
were considered to be of moderate importance only, by the 
majority (Table 9). 
Thus the final core-outcome set contains 15 items, over 4 do-
mains (Table 10). 
Discussion
While at first glance this list may seem to be too extensive, the 
items are spread over 4 key domains. Three key patient rated 
symptoms: nasal obstruction, nasal discharge and sense of smell 
are included, alongside overall symptom severity and both 
frequency and duration of symptoms. Repeated use over time 
of a PROM that includes these symptoms will allow both the 
symptom scores and duration of symptoms as well as duration 
of treatment effect to be measured. PROMs such as the SNOT-22 
also include items on ability to perform normal daily activity and 
will evaluate overall disease specific quality of life. 
A measure of treatment compliance, alongside evaluation of the 
side effects of any treatment should be included in future trials, 
and likely obviates the need for a separate question on accepta-
bility of treatment. Endoscopy scores were considered essential 
within the outcome set. This is most commonly graded using 
the Lund-Kennedy score. 
Finally a measure of disease control was thought to be impor-
tant. Control of disease is a concept that combines current 
disease status or symptom burden and the level of intervention 
required to get there. The Sinus Control Test is made up of 4 
questions, including severity of nasal discharge, nasal obstruc-
tion, frequency of symptoms that interfere with normal activity 
and need for systemic medication in the last 2 weeks (19). The 
EPOS guidelines (16) defined uncontrolled disease as the pres-
ence of 3 or more of the following; ‘bothersome’ symptoms of 
nasal obstruction, discharge, facial pain anosmia, sleep distur-
bance, abnormal endoscopy or systemic medication needed to 
control disease. This definition was evaluated by Harvey et al., 
who found better agreement with physician and patient rated 
control using a modified version of only 3 items; severity of nasal 
obstruction, abnormal endoscopy, and requirement for systemic 
medication in the last 3 months (the NOSE staging system of 
disease control)(20). Key to disease control in all of these control 
measures is the need for systemic medications – either oral 
steroids or antibiotics, which could be evaluated alongside the 
SNOT-22. The need for surgical intervention was rated as an 
essential outcome in the COS and is also a reflection for disease 
control. Indeed, a number of trials for biological agents are 
including avoidance of surgery as an outcome, and particularly 
in terms of cost-effectiveness evaluation this will be a great 
importance. Currently surgery represents the highest costs in 
the patient pathway with CRS, although this may change in the 
era of monoclonal antibodies. 
Many aspects of the COS are captured by the SNOT-22; a 
modification of the SNOT-22 to include a question of need for 
systemic medication or progression to surgery, compliance with 
and side effects of treatment, more information on frequency 
of symptoms and impact on ability to perform normal activi-
ties would better meet the needs of the COS. Of course, any 
modification of the SNOT-22 from its current form would require 
further re-validation. Thus, although 15 individual items were 
agreed to be important in the COS, these could be measured 
by a single PROM repeated over time, in conjunction with the 
Lund-Kennedy endoscopic score. 
This project aimed to define what outcomes should be inclu-
ded in a COS. The Steering Group agreed that it was important 
to make provisional recommendations regarding how these 
outcomes should be measured. Further work is now required to 
further develop and revalidate existing outcome measures. 
One strength of this project is the extensive work to develop the 
long-list of outcomes, including thematic analysis of views of 
patients and practitioners and a systematic review of outcomes 
used in CRS research. Our major limitation is that the response 
rate between Delphi rounds was lower than expected. This was 
in part due to delays in between rounds and problems using the 
electronic Delphi tool, which was newly launched at the time of 
use. We had planned to undertake 3 rounds, but analysis sug-
gested that stability had been reached and that further rounds, 
with risk of greater drop out would be unlikely to significantly 
change the final COS.
It is not intended that these core outcomes are the only outco-
mes that will be measured by trials of interventions for CRS, and 
researchers can of course add additional outcomes to suit the 
needs of specific trials. However, we hope that inclusion of these 
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core outcomes in all future trials will increase the value of future 
research on interventions for CRS in adults.
Implementation
We plan to seek endorsement from the European and American 
Rhinologic Societies in the first instance and ask for the COS to 
be included in future iterations of International guidelines such 
as EPOS and ICARS (21). We will make contact with major funding 
bodies (eg. NIHR in the UK and NIH in North America) to encou-
rage inclusion of core outcomes in trials at the point of funding.
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